Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3β pathway

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 65-70

  Zhu, H ^a,b   Han, B ^c   Pan, X ^a   Qi, H ^b   Xu, L ^a  

^a QINGDAO UNIVERSITY   (China)

^b Municipao Hospital   (China)

^c Qingdao 8th People's Hospital   (China)

Author keywords

Akt; apoptosis; glycogen synthase kinase 3 ; proliferator activated receptor ; prostate cancer; thiazolidenediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; COLORIMETRY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; THIAZOLIDINEDIONES;

EID: 84863054958     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01251.x     Document Type: Article

References (26)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ, Cancer statistics. CA: A Cancer Journal for Clinicians, 2003; 53: 5-26.
2. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT, Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer, 2003; 98: 1169-1178. (Pubitemid 37099901)
3. Deep G, Agarwal R, Chemopreventive efficacy of silymarin in skin and prostate cancer. Integrative Cancer Therapies, 2007; 6: 130-145. (Pubitemid 46871840)
4. Day C, Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medicine, 1999; 16: 179-192.
5. Koeffler HP, Peroxisome proliferator-activated receptor gamma and cancers. Clinical Cancer Research, 2003; 9: 1-9. (Pubitemid 36109710)
6. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Research, 1998; 58: 3344-3352. (Pubitemid 28371075)
7. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2000; 97: 10990-10995.
8. Kumagai T, Ikezoe T, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clinical Cancer Research, 2004; 10: 1508-1520. (Pubitemid 38365247)
9. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS, Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Research, 2005; 65: 1561-1569. (Pubitemid 40270186)
10. Li B, Sun A, Youn H, et al. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis, 2007; 28: 572-583. (Pubitemid 46523353)
11. Cho YL, Lee KS, Lee SJ, et al. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Biochemical and Biophysical Research Communications, 2005; 326: 752-758.
12. Dorai T, Aggarwal BB, Role of chemopreventive agents in cancer therapy. Cancer Letters, 2004; 215: 129-140. (Pubitemid 39370030)
13. Sun SY, Hail N Jr, Lotan R, Apoptosis as a novel target for cancer chemoprevention. Journal of the National Cancer Institute, 2004; 96: 662-672. (Pubitemid 38660229)
14. Sinha R, El-Bayoumy K, Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Current Cancer Drug Targets, 2004; 4: 13-28. (Pubitemid 38332561)
15. Jope RS, Yuskaitis CJ, Beurel E, Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochemical Research, 2007; 32: 577-595. (Pubitemid 46481289)
16. Wagman AS, Johnson KW, Bussiere DE, Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Current Pharmaceutical Design, 2004; 10: 1105-1137.
17. Doble BW, Woodgett JR, GSK-3: tricks of the trade for a multi-tasking kinase. Journal of Cell Science, 2003; 116: 1175-1186. (Pubitemid 36410657)
18. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR, Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO Journal, 2005; 24: 1571-1583. (Pubitemid 40646447)
19. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B, Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology, 2004; 145: 2941-2949. (Pubitemid 38686243)
20. Liao X, Zhang L, Thrasher JB, Du J, Li B, Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Molecular Cancer Therapeutics, 2003; 2: 1215-1222.
21. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr, Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Medicine, 1999; 5: 412-417. (Pubitemid 29180579)
22. Embi N, Rylatt DB, Cohen P, Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. European Journal of Biochemistry, 1980; 107: 519-527.
23. Frame S, Cohen P, GSK3 takes centre stage more than 20 years after its discovery. Biochemical Journal, 2001; 359: 1-16. (Pubitemid 32939202)
24. Rogatsky I, Waase CL, Garabedian MJ, Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. Journal of Biological Chemistry, 1998; 273: 14315-14321. (Pubitemid 28319147)
25. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA, Gautam SC, Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. Journal of Pharmacology and Experimental Therapeutics, 2007; 321: 616-625. (Pubitemid 46624498)
26. Jiang M, Shappell SB, Hayward SW, Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. Journal of Cellular Biochemistry, 2004; 91: 513-527.